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Abstract
Parasitic roundworm infections plague more than 2 billion people (1/3 of humanity) and cause drastic losses in crops and
livestock. New anthelmintic drugs are urgently needed as new drug resistance and environmental concerns arise. A
‘‘chokepoint reaction’’ is defined as a reaction that either consumes a unique substrate or produces a unique product. A
chokepoint analysis provides a systematic method of identifying novel potential drug targets. Chokepoint enzymes were
identified in the genomes of 10 nematode species, and the intersection and union of all chokepoint enzymes were found.
By studying and experimentally testing available compounds known to target proteins orthologous to nematode
chokepoint proteins in public databases, this study uncovers features of chokepoints that make them successful drug
targets. Chemogenomic screening was performed on drug-like compounds from public drug databases to find existing
compounds that target homologs of nematode chokepoints. The compounds were prioritized based on chemical properties
frequently found in successful drugs and were experimentally tested using Caenorhabditis elegans. Several drugs that are
already known anthelmintic drugs and novel candidate targets were identified. Seven of the compounds were tested in
Caenorhabditis elegans and three yielded a detrimental phenotype. One of these three drug-like compounds, Perhexiline,
also yielded a deleterious effect in Haemonchus contortus and Onchocerca lienalis, two nematodes with divergent forms of
parasitism. Perhexiline, known to affect the fatty acid oxidation pathway in mammals, caused a reduction in oxygen
consumption rates in C. elegans and genome-wide gene expression profiles provided an additional confirmation of its mode
of action. Computational modeling of Perhexiline and its target provided structural insights regarding its binding mode and
specificity. Our lists of prioritized drug targets and drug-like compounds have potential to expedite the discovery of new
anthelmintic drugs with broad-spectrum efficacy.
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Introduction
Parasitic nematode (roundworm) infections impose an enor-
mous burden of morbidity on humanity [1,2]. Only a few drugs
are commonly used to treat nematode infections, creating a
dangerous environment for the emergence of drug resistance.
Currently, administering anthelmintic drugs on a yearly basis is
necessary to break the infection cycle, but also causes drug
resistance in parasites that infect human and animal populations
[3,4]. Many of the drugs used to treat filarial infections, including
diethylcarbamazine (DEC), ivermectin, and albendazole, predom-
inately kill nematodes in their microfilarial stage and have a much
lower activity level in adult worms [5]. Plant parasitic nematodes
have devastating effects on crops, costing $78 billion per year
globally [6]. In addition to the possibility of the development of
pesticide resistance in plant parasitic nematodes, there are also
environmental concerns associated with them. For example, the
United States is phasing out methyl bromide (a highly effective
pre-plant soil fumigant used on high-value crops) due its ability to
deplete ozone in the stratosphere [7]. Thus, there is a pressing
need to develop new anthelmintic treatments and pesticides [1]
that are highly efficient and environmentally safe.
A systematic way of identifying new targets is by studying
metabolic pathways, particularly chokepoint reactions within
particular pathways. A ‘‘chokepoint reaction’’ is defined as a
reaction that either consumes a unique substrate or produces a
unique product (Figure 1A & B; [8]). If the enzyme catalyzing a
reaction that produces or consumes a unique compound can be
inhibited, the entire pathway will be blocked, leading to accumu-
lation of the unique substrate or the organism being starved of
unique product [8]. The idea of chokepoints and essentiality is
further supported by Palumbo et al [9], which demonstrated that
lethality corresponds to a lack of alternative pathways in a network
that has been perturbed by a blocked enzyme.
PLOS Pathogens | www.plospathogens.org 1 August 2013 | Volume 9 | Issue 8 | e1003505
Chokepoint analyses have been used for drug target identifica-
tion in several pathogenic organisms. In two different studies,
chokepoint analyses were performed to determine novel drug
targets for two parasites: the mitochondrial protist, Entamoeba
histolytica [10], and the protozoan parasite Plasmodium falciparum,
which causes malaria [8]. Two additional studies have applied
chokepoint analysis to find unique drug targets for Pseudomonas
aeruginosa [11] (a common bacterium that causes infections) and
Bacillus anthracis [12] (the bacterium that causes anthrax). Another
study which explored P. falciparum drug targets has evaluated the
essentiality of a reaction in a pathway by deleting a reaction in silico
and determining if the metabolic network could find an alternative
pathway to get to the same endpoint [13]. A chokepoint analysis
and the essentiality of a reaction have been combined to find
antibacterial drug targets [14]. However, most of these studies
have yielded a long list of chokepoints without any prioritization
for testing.
The number of nematodes sequenced has risen dramatically
recently, with a total of 10 complete nematode genomes being
published and around 30 in progress [15,16]. These newly
sequenced genomes provide a unique opportunity to find new
anthelmintic drug targets that may be broad-spectrum in nature.
The set of 10 sequenced nematode genomes provides represen-
tatives from four of the five clades spanning the phylum Nematoda
[17] including those that are free-living, and plant, animal, or
human parasitic nematodes. In this study, we determine
chokepoint reactions using the intersection in all 10 nematode-
deduced proteomes (the common/intersection to all ten studied
nematodes, CommNem), as well as the complete set of
chokepoints within the 10 deduced proteomes (the union of all
10 nematode species, UniNem). We also isolate a group of
chokepoints that are only found in a union of parasitic nematodes
(ParaNem). All other chokepoint analysis studies have only used a
single organism in their analysis, making this pan-phylum analysis
much more comprehensive than previous studies. The chokepoints
from nematodes are compared to chokepoints in Drosophila
melanogaster and Homo sapiens, in addition to the chokepoints found
in the publicly available databases, KEGG Drug and DrugBank
Figure 1. Workflow for identification, characterization, and prioritization of chokepoint drug targets and drug-like compounds. A.
& B. The chokepoint compounds are shown in yellow. A ‘‘chokepoint reaction’’ either consumes a unique substrate or produces a unique product. In
A., the chokepoint reaction (red) consumes a unique substrate (yellow). Five compounds are involved in reactions (blue) that produce the substrate
for the chokepoint reaction. In B., the chokepoint reaction (red) produces a unique substrate, which is subsequently used in other reactions to create
five new compounds (grey). C. Workflow diagram outlining the major steps in this study.
doi:10.1371/journal.ppat.1003505.g001
Author Summary
The World Health Organization estimates that 2.9 million
people are infected with parasitic roundworms, causing
high-morbidity and mortality rates, developmental delays
in children, and low productivity of affected individuals.
The agricultural industry experiences drastic losses in crop
and livestock due to parasitic worm infections. Therefore,
there is an urgent need to identify new targets and drugs
to fight parasitic nematode infection. This study identified
metabolic chokepoint compounds that were either pro-
duced or consumed by a single reaction and elucidated
the chokepoint enzyme that drives the reaction. If the
enzyme that catalyzes that reaction is blocked, a toxic
build-up of a compound or lack of compound necessary
for subsequent reaction will occur, potentially causing
adverse effects to the parasite organism. Compounds that
target some of the chokepoint enzymes were tested in C.
elegans and several compounds showed efficacy. One
drug-like compound, Perhexiline, showed efficacy in two
different parasitic worms and yielded expected physiolog-
ical effects, indicating that this drug-like compound may
have efficacy on a pan-phylum level through the predicted
mode of action. The methodology to find and prioritize
metabolic chokepoint targets and prioritize compounds
could be applied to other parasites.
Metabolic Chokepoints in Nematodes
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[18,19]. Further, targets of insecticides were also investigated. We
confirm that chokepoints are meaningful drug targets by
identifying chokepoint enzymes that are already known anthel-
mintic and insecticide targets through this method. Given the list
of nematode chokepoints, we prioritize the list by evaluating
specific criteria and compare the results to known drug targets
from two publically available databases. In addition, we provide a
list of enzymes involved in chokepoint reactions that have already
known drug associations. Seven of these compounds (referred to as
‘‘drug-like compounds’’ because while pharmacological properties
were used to screen out compounds, not all of the compounds in
those databases are approved drugs) were experimentally tested in
C. elegans and two parasitic nematodes. Three drug-like com-
pounds elicited a deleterious phenotype in C. elegans, and one of
these also yielded a deleterious phenotype in the two parasitic
species, demonstrating that this prioritized list of drug-like
compounds should be further studied for good candidates for
repositioning and/or development as potential anthelmintic drugs.
We present evidence that one of these drug-like compounds,
Perhexiline, acts according to its predicted mode of action.
Computational modeling suggested structural differences in the
binding site that can be used to develop a more specific, efficacious
drug.
Materials and Methods
Proteomes (Deduced from Whole Genomes) Databases
The following list of nematode genomes was analyzed: Brugia
malayi [20], Caenorhabditis species from WormBase release WS240
(Caenorhabditis brenneri, Caenorhabditis briggsae, Caenorhabditis elegans,
Caenorhabditis japonicum, Caenorhabditis remanei), Meloidogyne hapla
(http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/cgi-bin/gen
_list.cgi?genome = wm; [21]), Meloidogyne incognita (http://www.inra.
fr/meloidogyne_incognita/g enomic_resources/downloads; [22]),
Pristionchus pacificus (http://pristionchus.org; [23]) and Trichinella
spiralis [24]. The Homo sapiens genome was downloaded from
Ensembl (Homo_sapiens.GRCh37.57.pep.all.fa) and Drosophilia
melanogaster were downloaded from Flybase 5.26 (http://flybase.
org/static_pages/downloads/archivedata3.html). The sequences of
all the genomes had open reading frames discerned and then
translated to protein for analysis (henceforth referred to as
‘proteomes’). Proteins with EC (enzyme commission) numbers
associated with them were downloaded from KEGG version 58
[18]. WU-BLASTP (wordmask-seg, hitdist = 40, topcomboN = 1,
postsw) was used to screen the proteomes for sequence similarity
and find homology to proteins with an associated EC number and
best match, scoring below 1e210. The intersection of ECs (i.e.
common ECs, ‘‘CommNem’’) and the union of ECs (i.e. set of all
nematode ECs, ‘‘UniNem’’) in the 10 nematode proteomes were
parsed using PERL scripts developed in-house.
Drug Databases
Both KEGG Drug [18] and DrugBank [19] were used to
identify potential drugs that bind to targets in the nematode
proteomes, H. sapiens, and D. melanogaster. These databases contain
some FDA approved compounds, as well as compounds that were
known to interact with certain targets. The KEGG Drug and
DrugBank databases used for analysis were downloaded on 4/14/
2010 and 5/19/2010, respectively. ECs were linking to targets
using annotations from the KEGG Drug database. DrugBank
contains the protein sequences of the targets, as well as their
associated drugs. WU-BLASTP was used to screen the targets in
DrugBank against the KEGG genes database to get an EC
number annotation that matched within a cutoff score of 1e210 or
better. The EC number associated with the DrugBank target was
then associated with the drug within DrugBank.
Identifying Chokepoints
The reaction database from KEGG v58 [18] was used to
identify chokepoint reactions and corresponding chokepoint
enzymes. Each reaction equation is listed as a separate reaction
with a unique identifier under the ENTRY field. The KEGG
reaction database also contains a file that lists the reactions within
the reaction database as reversible or irreversible (reaction_
mapformula.lst – downloaded 6/21/2011). The entire reaction
was extracted from the KEGG reaction database by parsing the
EQUATION field, and the reaction_mapformula.lst file was used
to obtain the directionality of the reaction such that the reactions
could be written with reactants on the left side and products on the
right side. If the reaction was reversible, this was also noted in the
file because products and reactants would be ambiguous. The
reactions were placed into a [compound6reaction number]
matrix by parsing an intermediate file that contained the
directionality and all the products and reactants for the reaction
within the matrix, 21 indicated the compound was consumed (i.e.
the compound was listed on the left side of the equation), +1
indicated the compound was produced (i.e. the compound was
listed on the right side of the equation), 2 indicated the reaction
was reversible, and a zero indicated the compound did not take
part in the reaction. To find the chokepoints, the matrix was
parsed for compounds that were only produced or consumed in a
single reaction. If a compound was produced or consumed in a
single reaction, only a single 1 or 21 would be present across the
entire compound row within the matrix. In some cases, a
compound was uniquely produced or uniquely consumed, but
was part of a reversible reaction (i.e. two 2’s would be present
within a row). If this reaction was the only reaction in which the
compound participated, this was also called a chokepoint. The
chokepoint compounds were related to EC numbers using the
ENZYME field in the reaction database.
Pathway Participation
The EC numbers corresponding to proteins in the various
genomes were mapped to KEGG metabolic pathways active in
nematodes. Pathway categories that were not applicable such as
photosynthesis, carbon fixation, reductive carboxylate cycle were
excluded. The distribution of chokepoint targets and known drugs
in metabolic pathways was compared to determine any potential
enrichment using Fisher’s Exact Test.
Chokepoint Localization in Pathways
Pathways in the KEGG reaction database (v58) were enumer-
ated. First, the KEGG reaction database was broken into separate
reaction pathways based on the ‘‘PATHWAY’’ classification.
There were 8121 entries in the reaction database, and 5638 had a
PATHWAY classification. Only 142 unique reaction pathways
were used; due to the large size and overlap with other pathways,
rn00240, rn00230, rn01100, rn01110, and rn01120 were not used.
For each of the different pathways, a separate [compound6reac-
tion number] matrix was generated as described in the ‘‘Identi-
fying Chokepoints’’ section above. The starting and ending nodes
for reaction pathways were generated from this matrix by
determining compounds that were consumed but not produced
(start nodes) and produced but not consumed (end nodes).
Beginning with each of the start nodes, the compounds in all
possible pathways were enumerated. The position of the
chokepoint within the pathway was determined by the number
Metabolic Chokepoints in Nematodes
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of compounds in the pathway before the chokepoint, as well as the
length of the entire pathway.
Prioritization of Chokepoint Reactions and Targets
Chokepoint enzymes were prioritized by assigning a point for
meeting each of the following criteria, then ranked based on
number of points: EST-based gene expression found in a parasitic
stage for plant parasitic nematodes (egg, J2, J3, J4, adult) and
infective/parasitic stages for human and animal parasitic nema-
todes (embryo, L3, L4, adults); expressed in pharynx, intestine,
neurons, muscle, or hypodermis [25,26,27] in C. elegans (www.
wormbase.org); less than 30% sequence identity to H. sapiens over
half the length of the sequence; chokepoint enzyme functioning in
two or more pathways; chokepoint enzyme involved in nucleic
acid metabolism; and chokepoint is a hydrolase based on their
enrichment (classification as EC 3, enzyme commission number).
This analysis was performed to determine if certain classes of
enzymes were more likely to have drugs associated with them. This
information was fed into the prioritization scheme. EST sequences
sets for the 10 species were downloaded from Genbank on 7/16/
2010: C. brenneri, C. briggsae, C. japonicum, M. hapla, M. incognita, T.
spiralis, P. pacificus, B. malayi, and C. remanei. C. elegans EST
sequences were downloaded from GenBank on 4/21/2010. The
tissue expression data from C. elegans was obtained from
WormMart (WS195) on 4/23/2010.
Chemogenomic Screening for Compound Prioritization
Proteins associated with ECs (using KEGG) were blast searched
against protein targets in DrugBank as described above. The ECs
from DrugBank were compared to CommNem and UniNem.
Cheminformatic properties were obtained by running SMILES
strings (SMILES are strings of ASCII characters that describe a
compound unambiguously) extracted from DrugBank through the
Cytoscape [28] plugin, ChemViz. To prioritize the drugs, drugs
were given one point for meeting each of the following criteria:
molecular weight #500, 0,number of rotatable bonds #10,
hydrogen-bond donors #5, hydrogen-bond acceptors #10,
logP#5 [29]. This additional screen was done because the
compounds in the drug database are not optimized for Lipinski’s
rules and thus may not have been ‘‘successful’’ drugs for the
disease for which they were developed/tested. For a drug to be
effective, it should have a long half-life, so a drug with half-life
$60 minutes was rewarded with a point. Toxicity information is
also important for future testing and therefore, a compound with
any available toxicity information was given an additional point.
The maximum attainable compound score was 7. Drug-like
compounds were also eliminated if placed in the dietary
supplement, micronutrient, or vitamin categories by DrugBank,
as various vitamins and amino acids were not desired. Nematode
proteins were searched against sequences from DrugBank, and
then parsed for sequences that had 50% or greater identity over
80% of sequence length. Only these targets were considered in the
prioritized list.
Compound Screen in Caenorhabditis elegans
Compounds were obtained from the following sources: Perhex-
iline maleate (1 DB1074 is just perhexiline; CAS: 6724-53-4;
P287320) from TRC; Carbidopa (2 DB00190; CAS: 28860-95-9;
BML-EI265) and dopamine (4 DB00988; CAS: 62-37-1; BML-
AC752) were ordered from Enzo Life Sciences dissolved in
DMSO; LT00772250 (Probenecid 5 DB01032; CAS: 57-66-9),
LT00255846 3 (similar to DB00993; the DrugBank compound
was not available, so a similar compound was ordered),
LT00138053 (6 DB01033), LTBB001666 (7 DB00548) were
ordered from Ryan Scientific. Compounds formulated in 100%
DMSO were tested in microtiter plates containing 50 ml nematode
growth media, 1% E. coli and 20 L1 C. elegans. Five concentrations
in 4-fold increments (0.078, 0.3125, 1.25, 5, and 20 ppm; ,25 to
60 mM, depending on the molecular weight of the compound)
were tested, and the experiment was repeated twice and a final
confirmation test, with the best result reported. The efficacy of a
compound was determined based on the motility of the larvae as
compared to average motility of control wells containing DMSO
only at 48 hours post treatment (by that time the larvae develop to
L4’s; screening is not performed at a later stage due to the way
imaging is done, i.e. comparing exact numbers of parasites in
every well). The motility was assessed using a camera-based
imaging. The camera takes multiple images of a well and the
changes in movement between the images are calculated. An
absolute movement value is calculated for each well. On each test
plate, multiple wells containing only DMSO are included as a
control. The absolute movement value from these wells was
averaged and then compared to the movement in the treatment
wells. The percent reduction in motility is calculated by dividing
the movement in the treatment well by the average movement of
the DMSO wells. Controls were used on every plate and in every
test (data not shown). Movement was manually assessed at
72 hours post-treatment to determine if there were altered
movements or morphological changes not detected by the imaging
system.
Compound Screen in Parasitic Nematodes
Compounds formulated in 100% DMSO were tested in
microtiter plates containing 50 ml nematode media, fecal slurry
and 20 L1 Haemonchus contortus. The experiment was repeated twice
at five concentrations in 4-fold increments (0.078, 0.3125, 1.25, 5,
and 20 mM). The efficacy of a compound was determined based
on the motility of the larvae (when the larvae have developed to
L3’s) as compared to average motility of control wells containing
DMSO only. A MIC90 value was calculated by determining the
lowest dose at which there was a 90% reduction in motility as
compared to the control wells. The motility was assessed using a
camera-based imaging system as described in the C. elegans screen.
Larval movement was manually assessed at 72 hours post-
treatment to determine if there were altered movements or
morphological changes not detected by the camera.
Compounds were tested at two static doses of 50 mM and
12.5 mM in Onchocerca lienalis. Five microfilariae were added to
each well of a 96-well microtitre plate. Larvae were assessed at
120 hours post-treatment and efficacy was determined by visually
assessing the motility of the larvae in the treated wells as compared
to control wells.
While other stages for screening could also be used, our
approach was implemented as an early indicator of activity.
Progressing to advanced tests against relevant clinical stages should
be the next step for future research. In particular, when working
with filarial worms, having some filter for prioritizing compounds
is helpful, since access to adult stages is often difficult.
Measurement of Oxygen Consumption Rates
Real-time measurements of oxygen consumption rates (OCR)
were made using an XF-24 Extracellular Flux Analyzer (Seahorse
Bioscience) as previously described [30]. The real-time extracel-
lular flux experiment was designed to evaluate whether Perhexiline
decreases OCR via inhibiting mitochondrial carnitine palmitoyl-
transferase in C. elegans. The concentrations used (25–100 uM) do
not have any impact on the movement of the worms (based on
examination under the microscope), but do have an impact on the
Metabolic Chokepoints in Nematodes
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OCR. Synchronized young adult C. elegans were washed with M9
media and plated into XF-24 culture plates at approximately 100
worms/well. OCR measurements were recorded under basal
conditions or in the presence of Perhexiline, Etomoxir (Sigma)
and/or Ivermectin (Sigma) at various concentrations, over a
period of 1.5 hours and 40 minutes. The significance of observed
OCR differences was assessed using Student’s t-test using
GraphPad Prism Version 5.
RNA Extraction and RNAseq Data Generation
The treated worms (approximately 100 ml settled volume) were
washed in sterile PBS and resuspended in 100 ml TRIzol reagent
(Invitrogen). Samples were frozen with liquid nitrogen and
homogenized. Following the homogenization, the worm/TRIzol
powder was collected and allowed to thaw on ice. A further 0.2
volumes of chloroform were added into samples, and gently
mixed, incubated at room temperature for 3 minutes, then
centrifugated at 12,0006 g for 15 minutes at 4uC. The upper
aqueous phase was transferred to a fresh tube and RNA was
precipitated by an additional 0.5 volumes of isopropanol followed
by incubation at room temperature for 10 minutes. The mixture
was then centrifuged at 12,0006 g for 10 minutes at 4uC. The
supernatant was discarded and the RNA pellet was washed with
500 ml of 75% (v/v) ethanol before centrifugation at 7,5006 g for
5 minutes at 4uC. The supernatant was removed and the pellet
air-dried. The RNA pellet was suspended in nuclease-free distilled
water.
The total RNA was treated with Ambion Turbo DNase
(Ambion/Applied Biosystems, Austin, TX). 1 ug of the DNAse
treated total RNA went through polyA selection via the
MicroPoly(A) Purist Kit according to the manufacturer’s recom-
mendations (Ambion/Applied Biosystems, Austin, TX). 1 ng of
the mRNA isolated was used as the template for cDNA library
construction using the Ovation RNA-Seq version 2 kit according
to the manufacturer’s recommendations (NuGEN Technologies,
Inc., San Carlos, CA). Non-normalized cDNA was used to
construct Multiplexed Illumina paired end small fragment libraries
according to the manufacturer’s recommendations (Illumina Inc,
San Diego, CA), with the following exceptions: 1) 500 ng of cDNA
was sheared using a Covaris S220 DNA Sonicator (Covaris, INC.
Woburn, MA) to a size range between 200–400 bp. 2) Eight PCR
reactions were amplified to enrich for proper adaptor ligated
fragments and properly index the libraries. 3) The final size
selection of the library was achieved by an AMPure paramagnetic
bead (Agencourt, Beckman Coulter Genomics, Beverly, MA)
cleanup targeting 300–500 bp. The concentration of the library
was accurately determined through qPCR according to the
manufacturer’s protocol (Kapa Biosystems, Inc, Woburn, MA) to
produce cluster counts appropriate for the Illumina platform. The
HiSeq2000 Illumina platform was used to generate 100 bp
sequences.
Analytical Processing of the Reads and Differential
Expression
Analytical processing of the Illumina short-reads was performed
using in-house scripts. DUST was used to filter out regions of low
compositional complexity and to convert them into N’s [31]. An
in-house script was used to remove N’s, which discards reads
without at least 60 bases of non-N sequence. Raw RNA-seq
datasets are deposited at SRA (accession numbers: Control -
SRR868958, IVM - SRR868932, PER - SRR868957, PER+ETO
- SRS868939, ETO - SRS868942.). Gene expression for each
sample was calculated by mapping the screened RNA-seq reads to
the WS230 release of C. elegans using Tophat [32] (version 1.3.1),
and calculating depth and breadth of coverage per gene using
Refcov (version 0.3, http://gmt.genome.wustl.edu/gmt-refcov).
Gene expression values were normalized using the depth of
coverage per million reads (DCPM) per sample [33]. Expressed
genes were subject to further differential expression analysis using
EdgeR [34] (false discovery rate ,0.05, dispersion value 0.01), in
order to identify genes differentially expressed in each treatment
relative to the control sample. Hierarchical agglomerative
clustering (with ‘‘unweighted pair group method with arithmetic
mean’’, and Pearson correlation coefficient similarity settings in
XLSTAT-Pro; version 2012.6.02, Addinsoft, Inc., Brooklyn, NY,
USA) was used to cluster samples based on the gene expression
profiles across all genes, and to cluster all 1,908 genes upregulated
in any of the four comparisons.
Functional Annotation and Enrichment
Interproscan [35,36] was used to determine associations of
genes to Gene Ontology (GO) terms [37]. Interproscan also
identified predicted Interpro domains found in each gene. GO
term enrichment among genes upregulated in each of the 4
samples was determined using a non-parametric binomial
distribution test with a 0.05 p value cutoff for significance, after
Benjamini-Hochberg false-discovery-rate (FDR) population cor-
rection for the total number of terms [38]. Only GO terms with at
least 5 gene members in the C. elegans genome were included in the
analysis (501 total).
Docking Perhexiline
Perhexiline was downloaded from the DrugBank website as a
mol file, then converted to a PDB file using OpenBabel [39]. The
PDB file was optimized using Sybyl 7.3 [40] to minimize the
Perhexiline structure. In AutoDockTools4 [41], hydrogen atoms,
followed by Gasteiger charges, were added, then the non-polar
hydrogen atoms were merged. A docking box of 88668680 points
in the x, y, and z dimensions, with a spacing of 0.375 A˚, was used
centered at 61.752, 72.8001, 52.0321 and all other parameters
were default. The carnitine palmitoyltransferase-2 (CPT-2) mac-
romolecule was taken from the crystal structure of 2H4T [42].
Hydrogen atoms were added, followed by Kollman charges. Then,
the non-polar hydrogens were merged on the macromolecule. The
docking calculations utilized local search Lamarkian genetic
algorithm in Autodock4 [41] using rigid side chains. A total of
250 genetic algorithm runs were done. The results were clustered
using Autodock4 with the default parameters.
Results
Identification of Chokepoint Enzymes and Their
Phylogenetic Distribution
Our approach identifies chokepoint enzymes as targets of
existing drugs or as novel drug targets (Figure 1C). The
intersection of nematode genomes (CommNem) yielded 487
proteins conserved among all nematode species studied, of which
169 are conserved chokepoint enzymes (Figure 2 & Table S1 in
Text S1). The union of the nematode proteomes (UniNem) yielded
477 chokepoint enzymes (Table S2 in Text S1), of which 24
chokepoint enzymes were only found in parasitic worms (Para-
Nem). The EC numbers and corresponding FASTA sequences for
each of the species investigated can be found on Nematode.net
[43]. In all cases, 34–35% of the proteome assigned with an EC
number consists of chokepoints (Figure S1 in Text S2). The only
chokepoint enzyme present in CommNem and not in H. sapiens is
EC: 6.2.1.12. However, 120 chokepoint enzymes from UniNem
are not found in H. sapiens. A high overlap also exists between
Metabolic Chokepoints in Nematodes
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CommNem chokepoint enzymes and D. melanogaster, with only 5 of
169 in CommNem are not present in D. melanogaster (EC: 1.8.4.2,
2.4.2.8, 5.3.2.1, 2.7.1.149, 3.6.1.14).
Chokepoint Enzyme Classification
Some enzyme categories were enriched or depleted based on
Fisher’s Exact statistical test within the species relative to
chokepoint enzymes in KEGG (i.e. KEGGChoke), and all
enzymes in the KEGG database (i.e. AllKEGG) (Figure S2 in
Text S2). This analysis was performed to determine if certain types
of enzymes were more likely to have drugs associated with them.
This information was fed into the prioritization scheme. Oxido-
reductases were significantly enriched in nematodes and KEGG
Drug and DrugBank relative to KEGGChoke (p,0.005). The
chokepoints within KEGG Drug and DrugBank were significantly
enriched in hydrolase enzymes (p,0.005) when compared to
KEGGChoke (all chokepoints in KEGG identified using our
approach) as well as AllKEGG (all enzymes with assigned ECs
within KEGG). Further, isomerases in DrugBank and KEGG
Drug were significantly enriched relative to KEGGChoke. The
abundances of enzymes in DrugBank and KEGG Drug signifi-
cantly differ from KEGGChoke in 3 out of the 6 enzyme
categories.
Anthelminth Chokepoints and Chemogenomic Screening
There are 75 drugs in KEGG Drug that are classified as
anthelmintic. Much research has also been done to design
insecticides, therefore it is interesting to see that these insecticides
also target chokepoint enzymes. The insecticides are shown in
Table S3 in Text S1, and the DrugBank compounds that are
classified as antiparasitic are shown in Table S4 in Text S1.
The nearly complete overlap of CommNem and partial overlap
of UniNem chokepoint enzymes with H. sapiens enzymes provide
an excellent opportunity to reposition drugs used for other
purposes in H. sapiens as anthelmintic drugs. If these drugs show
some efficacy, subsequent optimization studies could be performed
on these leads to make these drugs bind with higher affinity and
specificity to the nematode protein. Out of the 169 chokepoints in
CommNem, only 13 have a drug associated with them in KEGG
Drug (Table S5 in Text S1 and Table S6 in Text S1). When
considering UniNem, a total of 29 chokepoints have ECs
associated with a drug in KEGG Drug (Table S5 in Text S1
and Table S7 in Text S1). Out of 446 enzymes involved in
chokepoint reactions in H. sapiens, only 35 mapped to ECs
associated with a drug in KEGG (data not shown). Of the 977
enzymes in the D. melanogaster genome, 330 are chokepoint
enzymes and of the 68 of those that mapped to the ECs in the
KEGG Drug database 29 are considered chokepoint enzymes.
There are 30 drugs in KEGG that have insecticide activity, but
none have ECs associated with them. Only 97 enzymes within
KEGG Drug have an EC assigned, of which 39 are associated
with chokepoint reactions. Therefore, the UniNem, H. sapiens, and
D. melanogaster proteins hit roughly 1/3 of targets with ECs assigned
within KEGG Drug.
DrugBank contains the sequences of targets to which the drugs
bind, enabling more complete mapping of ECs to protein targets
and subsequently to drug-like compounds. Within DrugBank,
there are 4774 compounds, and 1289 targets were assigned EC
numbers. DrugBank contains 504 enzymes that are involved in
chokepoint reactions based on chokepoints derived from KEGG
reactions. Based on the number of compounds, KEGG Drug has
more compounds than DrugBank with 9447 compounds. How-
ever, DrugBank has many more compounds associated with ECs
(Figure S1 in Text S2). Due to the large list of targets and
compounds, the compounds were prioritized (see Methods).
Several of the compounds yielded the maximal compound score
of 7. A compound score cutoff of $6 was used to prioritize the top
drugs that have potential to be repositioned or further optimized
as nematode drugs (Figure 3A, Table 1). The compounds
identified are drugs that are used to treat hypertension, angina,
and Parkinson’s disease, and have immunosuppressive and
antimicrobial properties.
Figure 2. Proteins with Enzyme Commission (EC) classification
and chokepoint enzyme mapping. Intersection of A. Proteins with
EC classification and B. Chokepoint enzymes from CommNem, D.
melanogaster, and H. sapiens. The 487 proteins that are referred to in
the text from CommNem are derived from Figure 2A (7+465+15), and
the 169 proteins from CommNem that are conserved chokepoints are
derived from Figure 2B (5+163+1).
doi:10.1371/journal.ppat.1003505.g002
Figure 3. Chemical structures of drug-like compounds and
results from screening in C. elegans and H. contortus. A. The drug-
like compounds tested in the C. elegans, H. contortus, and O. lienalis
screens. 1 (perhexiline; DB01074), 2 (DB00190), 3 (LT00255846 -
DB00993 is a similar compound), 4 (DB00988), 5 (DB01032), 6
(DB01033), 7 (DB00548). B. Comparison of 8 (DB00190) from this study
and 9 (Methyldopa), which was shown to inhibit L-DOPA decarboylase
in S. mansoni. Dose-response curve for perhexiline (1) in C. C. elegans
and D. H. contortus.
doi:10.1371/journal.ppat.1003505.g003
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Chokepoint Characterization
Pathway population. Various groups of enzymes involved in
chokepoint reactions (including UniNem, CommNem, KEGG
Drug, and DrugBank) were compared to KEGGChoke and
AllKEGG. The enzymes in CommNem were involved in a
significantly greater number of multiple pathways than AllKEGG
and KEGGChoke (p,1024) (Figure S3A in Text S2). For the drug
databases, significantly fewer enzymes in KEGG Drug and
DrugBank were involved in just one pathway and significantly
more were involved in multiple pathways when compared to
KEGGChoke (p,0.02; Figure S3B in Text S2). When KEGG
Drug and DrugBank were compared to AllKEGG, there were
significantly fewer enzymes that were involved in just one pathway
(p,0.03). The information obtained from these tests was added to
the prioritization scheme, providing an additional point (resulting
in a higher score) for chokepoint enzyme involved in two or more
pathways due to higher likelihood to have a deleterious effect when
inhibited.
Chokepoint enzymes and potential drug targets may be
enriched in certain metabolic pathways. Where nematode-
appropriate pathways were considered (excluding pathways that
are not applicable, such as photosynthesis, etc, since the KEGG
pathways are a common set of pathways for prokaryotes and
eukaryotes), nucleotide metabolism was enriched significantly in
UniNem, CommNem, KEGG Drug, and DrugBank when
compared KEGGChoke (Figure 4). The enzymes in DrugBank
were enriched in several areas of nematode metabolism, including
nucleotide, energy, and carbohydrate metabolism, and depleted in
biosynthesis of secondary metabolism and xenobiotics biodegra-
dation compared to KEGGChoke. KEGG Drug was enriched in
two areas of metabolism: lipid and nucleotide compared to
KEGGChoke. CommNem was also enriched in enzymes involved
in amino acid metabolism when compared to KEGGChoke.
When the groups were compared to AllKEGG, enrichment for
UniNem included lipid metabolism, amino acid metabolism, and
metabolism of other amino acids. Enzymes with nucleotide and
amino acid metabolism were also significantly enriched in the
CommNem group compared to AllKEGG.
Position in pathway. The chokepoint position within their
respective pathway was calculated by taking the position in the
pathway divided by the total pathway length. The pathways
ranged in length from 3 to 36 reactions, with most pathways
within one standard deviation of the mean (15 reactions) being
10 to 21 reactions long. The positions of the chokepoint
compounds in the pathways were relatively evenly distributed
throughout the pathway in H. sapiens, D. melanogaster, and
CommNem, regardless of whether the compound was produced
or consumed. The position of chokepoint enzymes that already
have known drugs associated with them were mapped to their
position in the pathways. Chokepoint enzymes whose product
were consumed were enriched (using Fisher’s Exact Test)
around the point of 20% pathway length for anthelmintic
compounds (p,2e28) compared to ,60–70% of the pathway
length for chokepoints in KEGG Drug (p,2.2e216). Choke-
point enzymes whose compound was created were enriched
(using Fisher’s Exact Test) around the point of 50% pathway
length for anthelmintic compounds (p,4e215) compared to
around 70% for compounds in KEGG Drug (p,2.2e216). This
knowledge was not added to the prioritization, however,
because significant results were not obtained for chokepoint
enzymes in DrugBank. Additional testing would need to be
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Prioritization of Chokepoint Enzymes and Experimental
Testing
The chokepoint enzymes were prioritized for the CommNem,
UniNem, and ParaNem groups using a simple addition scoring
function, with 7 being the maximum possible target score (see
Methods and Materials). The results for CommNem and
UniNem are shown in Table 2 and ParaNem in Table S8 in
Text S1. The maximum target score obtained in CommNem and
UniNem was 5, and a cutoff of 4 was used. None of the enzymes
in ParaNem met the maximum-target score criteria as well, with
5 being the highest target score attained; therefore a cutoff of 2
was used.
Drug-like Compound Screening in C. elegans, H.
contortus, and O. lienalis
The seven drug-like compounds prioritized based on our cut-off
(see Methods and Materials) were experimentally screened in C.
elegans (Table 1), and three yielded a phenotype. C. elegans exposed
to drug-like compound 2 yielded a slow moving and twitchy
phenotype, whereas 7 yielded a jerky, twitchy phenotype in 75%
of the worms and 25% of the worms did not move after exposure
to the compound. C. elegans exposed to drug-like compound 1
(Perhexiline) yielded a 50% reduction in motility phenotype at
47.3 mM (18.6 ppm), also showed slow movement and twitchy
behavior at compound concentrations below the EC50 value.
Importantly, Perhexiline (1) caused a 90% reduction in motility
(MIC90) at 20 mM in the blood-feeding nematode H. contortus, and
100% reduction in motility in the filarial nematode O. lienalis at
50 mM. Chemical structures of the drug-like compounds are
shown in Figure 3A, dose-response curves for Perhexiline (1) are
shown in Figure 3C & D, and videos of the effect of Perhexiline (1)
on C. elegans and H. contortus and Carbidopa (2) and Azelaic acid (7)
in C. elegans are shown in Supplementary Videos (Video S1, S2, S3,
S4, S5, S6, S7, S8).
Measurement of Oxygen Consumption Rates
Carnitine palmitoyl transferases (CPT) are chokepoint enzymes
with existing drugs, such as Perhexiline (1), inhibiting the
mammalian homologs. Two versions of the enzyme (CPT-1 and
CPT-2) play important roles in fatty acid metabolism in the
mitochondria [44]. Inhibition of CPT leads to a decrease in
oxygen consumption rate (OCR) in the mitochondria. Perhexiline
(drug-like compound 1) treatment in C. elegans led to a significant
decrease in basal OCR in a dose-dependent manner (Figure 5A).
The effect of Perhexiline (PER) was equivalent to that of Etomoxir
(ETO), a known inhibitor of the mitochondrial outer membrane
associated enzyme, CPT-1, which acts with CPT-2 to regulate
fatty acid oxidation [45,46]. The combination of Perhexiline and
Etomoxir had an additive inhibitory effect of OCR that was
greater than the effects measured with either drug alone
(Figure 5B).
OCR was also measured in presence of PER, ETO, PER+ETO
and compared to OCR in presence of Ivermectin (IVM), a
commercially available anthelminic used to treat nematode
infections. IVM, which kills C. elegans at therapeutic concentrations
through interference with nervous system function, provides a
control for drug-induced toxicity that leads to phenotypic
alterations such as paralysis that may indirectly affect oxygen
consumption as measured by OCR. The dose response curve
(Figure 5C) enabled identification of the 10 uM concentration as
applicable for our comparison experiment (see Methods). While
the effect of PER, ETO and the additive inhibitory effect of OCR
was confirmed by this experiment, the IVM had no significant
inhibitory effect of OCR (Figure 5D).
Gene Expression Profiles of C. elegans after Exposure to
PER, ETO and IVM
Genome-wide gene expression profiling can be used to
investigate if a transcriptional response to drugs carries signatures
for drug mechanism of action. Drugs with related mechanisms of
Figure 4. Heatmap indicating enriched and depleted KEGG metabolic pathways. The extreme blue color indicates that the enzyme
category was significantly depleted and the extreme red color indicates the enzyme category was significantly enriched relative to either all
chokepoint enzymes or all the EC values from KEGG using Fisher’s Exact Test. The intermediate color shades indicate enrichment or depletion, but are
not statistically significant. Enrichment or depletion of metabolic pathways in UniNem, CommNem, DrugBank, and KEGG Drug compared to A.
AllKEGG and B. KEGGChoke. CommNem, intersection of nematode ECs; UniNem, set of all nematode ECs; KEGGChoke, chokepoint enzymes within
KEGG; AllKEGG, all enzymes within KEGG; DrugBank, ECs from DrugBank; KEGG Drug, ECs from KEGG Drug.
doi:10.1371/journal.ppat.1003505.g004
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action are expected to have similar patterns of molecular functions
significantly perturbed. RNAseq-based expression evidence was
obtained for all C. elegans genes with 6–11% of the genes being
differentially expressed among the four treatments (Table S9 in
Text S1). On average 2–8% of genes were upregulated (range
1.7% PER+ETO to 3.9% IVM) and 5.3% were downregulated
(range 3.3% PER to 7.1% IVM). Comparison of genome-wide
transcriptional responses to PER, ETO, PER+ETO and IVM
showed that the transcriptional responses of C. elegans to PER and
ETO are significantly closer than any of the two to IVM,
confirmed by them being clustered together and having more
enriched functions in common (Figure 6A; Table S10 in Text S1).
The correlation of gene expression (across the 1,908 differentially
expressed genes) between PER and ETO was 0.43, compared to
0.09 between PER and IVM (p,10210 according to r-to-z Fisher
test), showing that PER and ETO elicit a highly similar gene
expression response to one another compared to the IVM
treatment. PER and ETO cluster together since their targets
(CPT-1 and CPT-2) act together to regulate fatty acid oxidation.
The difference among PER and ETO, among others, was
reflected by a small gene expression cluster near the top of the
heatmap (Figure 6A), where we observed a group of genes
downregulated in PER but upregulated in ETO. GO enrichment
analysis on the genes related to this PER-specific downregulation
pattern identified several enriched molecular functions (flavin-
containing monooxygenase activity-GO:0004499; flavin adenine
dinucleotide binding-GO:0050660; carbohydrate binding-
GO:0030246 and NADP binding-GO:0050661) and biological
processes (response to heat-GO:0009408; multicellular organismal
development-GO:0007275). GO enrichment analysis was per-
formed independently on the upregulated gene sets of each of the
four treatments. The number of GO categories enriched in each
treatment are shown in Figure 6B, and the specific GO terms in
each intersection of Figure 6B can be found in Table S10 in Text
S1. Two terms, one biological process (response to heat-
GO:0009408) and one cellular component (peroxisome-
GO:0005777) were enriched among genes upregulated in PER,
ETO and PER+ETO, showing that both heat-responsive genes
(primarily HSP70 genes) as well as genes related to peroxisome
function were upregulated in all combinations of these treatments.
Since CPT-1 is an initiating step in the translocation of long chain
fatty acids across the mitochondrial membranes for beta-oxidation
[44,47] and the peroxisome proliferator activated receptor a
(PPARa) is a nuclear receptor which stimulates genes involved in
mitochondrial fatty acid oxidation and increases expression of
those modulating pyruvate oxidation, the observed enrichment of
genes related to peroxisome related activity is not surprising.
Among the 10 GO terms which were only enriched among the
PER+ETO treatment (but not in individual treatments) were two
biological process terms related to fatty acid processes (fatty acid
Table 2. Top prioritized chokepoint enzymes.
Groupa EC number
Target
score Name Type of enzyme Previous Indications as Drug Target
CommNem 3.5.2.2 5 dihydropyrimidinase Hydrolase Tumor suppressor target [68]
2.7.1.40 4 pyruvate kinase Transferase Drug target for P. falciparium [69] and bacteria [70]
2.7.4.6 4 nucleoside-diphosphate
kinase
Transferase Some are secreted in T. spiralis and may modulate host cell
function; Found to be consist. Trans. During all parasitic stages
in B. malayi. Did molecular modelling for drug targeting [58]
2.7.7.4 4 sulfate adenylyltransferase Transferase ----------------------
3.1.3.11 4 fructose-bisphosphatase Hydrolase Drug target for Type 2 diabetes [71]
3.1.3.5 4 59-nucleotidase Hydrolase Clinical vs Environmental isolates B. cepacia – secretion higher
in clinical – might be way bacteria evades immune system [72];
Inhibited by plant compounds lycorine and candimine in T.
vaginalis [55]; Inhibitors to treat melanomas, gliomas, breast




Hydrolase Drug target for P. falciparum [73] and kinetoplastids [74];
psychiatric and neurodegenerative diseases [75]
3.2.1.52 4 beta-N-
acetylhexosaminidase
Hydrolase Involved in chitin remodeling and drug target in T. vaginalis
[76]
3.5.4.5 4 cytidine deaminase Hydrolase Drug target for M. tuberculosis [77]; Anticancer therapeutic
potential [78]
3.5.5.1 4 Nitrilase Hydrolase Tumor suppressor target [79]
3.6.1.19 4 nucleoside-triphosphate
diphosphatase
Hydrolase Inhibited by plant compounds lycorine and candimine in T.
vaginalis [55]; New class of antischistosoma drugs partially




UniNem 3.1.3.1 4 alkaline phosphatase Hydrolase ----------------------
3.2.1.26 4 beta-fructofuranosidase Hydrolase ----------------------
3.5.1.6 4 b-ureidopropionase Hydrolase ----------------------
3.7.1.2 4 fumarylacetoacetase Hydrolase Target for treating tyrosinemia [80]
aAll CommNem targets are a subset of UniNem.
doi:10.1371/journal.ppat.1003505.t002
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Figure 5. Oxygen consumption rates in C. elegans after exposure to varying concentrations of Perhexiline (PER), Etomoxir (ETO) and
Ivermectin (IVM). A. Average basal oxygen consumption rates (OCR) of adult C. elegans incubated with vehicle (1% DMSO, 0 mM) or different
concentrations of PER (CPT-2 inhibitor) (25, 50 and 100 mM) over 90 minutes. B. Average OCR of adult C. elegans incubated with vehicle (1% DMSO,
Ctrl), ETO (CPT-1 inhibitor) (ETO, 50 and 100 mM), PER (50 and 100 mM), or 100 mM ETO plus 100 mM PER (ETO+PER) over 90 minutes. C. Average
based OCR of adult C. elegans incubated with vehicle (1% DMSO, 0 mM) or different concentrations of IVM (binds to glutamate-gated chloride
channels) over 40 minutes. D. Average OCR of adult C. elegans incubated with vehicle (1% DMSO, Ctrl), IVM (10 mM), PER (100 mM), ETO (100 mM), or
100 mM PER+100 mM ETO, over 40 minutes. Data are representative of at least 2 individual experiments. Bars represent the6SEM of 15 OCR readings
from 4 independent replicates per experiment. The experiment was repeated twice.
doi:10.1371/journal.ppat.1003505.g005
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beta-oxidation-GO:0006635 and fatty acid metabolic process-
GO:0006631), biological functions that are directly related to the
function of CPT-1 and CPT-2.
Docking of Perhexiline
The rat structure of CPT-2 (PDB ID: 2H4T) was used for the
docking of Perhexiline, since that is the only species with crystal
structures available. One major low-energy cluster with a binding
energy of 25.8 kcal/mol resulted and contained 226 of the 250
genetic algorithm runs. Using Autodock 4 [41], Perhexiline was
docked into the active site of CPT-2 [42] (Figure 7). The binding
site of Perhexiline in CPT-2 does not overlap with the carnitine
group in the ST-1326 (bound CPT-2 inhibitor in PDB ID: 2FW3)
based on the docking calculations, but overlaps more with the fatty
acid chain. The major contacts that Perhexiline makes in its
docked configuration include: P133, F134, M135, F370, H372,
D376, G377, V378, L381, S590, G601, and F602. H372 is the
catalytic residue (Figure 7C). The amine group on Perhexiline
makes a hydrogen bond with the backbone carbonyl group on
D376. Residues that differ between mammals and nematode
include L335, S445, Q447, V597, S598, L599, A615, W620,
C623, N624 (Figure 7B).
Discussion
Given the pressing need for new anthelmintic treatments and
pesticides, this study outlines new potential drug targets of global
importance found to be conserved in nematodes from different
trophic ecologies as well as promising compounds that could lead
to new anthelmintic treatments and nematicides. The targets offer
the possibility for broad-spectrum drugs and pesticides for
nematodes. We also provide a list of already known drugs that
could be repositioned or further optimized as anthelmintics.
Features of chokepoint enzymes that are known drug targets were
analyzed. This is the first study to incorporate a large dataset of
pan-phylum genomic data into a chokepoint analysis, provide a
prioritized list of targets for broad-spectrum drugs, and test some
of the prioritized drug-like compounds experimentally.
This work used the entire KEGG database to determine
chokepoint reactions, then compared the homologous enzymes
that are predicted to catalyze the chokepoint reactions in the
intersection (CommNem) and union (UniNem) of the 10
nematode species with sequenced genomes, as well as drug targets
in KEGG Drug and DrugBank. One caveat to this study is the
possibility that the absence of complete pathway information may
have led to false negative and false positive chokepoint drug
targets. For instance, the entire deduced proteomes of some
nematodes has not been mapped out due to the draft nature of the
genome sequences (e.g. B. malayi genome used in this study). Some
chokepoint reactions may utilize a chokepoint compound and
produce a product that is also produced by several other reactions.
To determine the effect of blocking the chokepoint reaction,
modeling of the kinetics and equilibrium constants within the
pathways would be required. However, these analyses are beyond
the scope of this work. Another caveat surrounding the databases
used in this study is the manner that compounds are linked to drug
Figure 6. Transcriptional response of C. elegans in the presence of Perhexiline (PER), Etomoxir (ETO) and Ivermectin (IVM). A.
Hierarchical clustering of samples based on gene expression patterns across all genes, and a heatmap based on differential expression profiles of
1,908 genes which were upregulated in at least one of the four samples relative to the control. B. Distribution of Gene Ontology enriched categories
among the upregulated genes in each of the four samples. The list of GO categories is provided as Table S10.
doi:10.1371/journal.ppat.1003505.g006
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Figure 7. Docking of Perhexiline to rat carnitine palmitoyltransferase 2 and sequence alignment of carnitine palmitoyltransferase 2
from mammals and nematodes. A. Part of the fatty acid metabolic pathway in KEGG that includes the chokepoint reaction (chokepoint enzyme
2.3.1.21, with its substrate (L-Palmitoylcarnitine) and product (Palmitoyl-CoA)) shown in red. Perhexiline is believed to bind to 2.3.1.21. B. Docked
structure of perhexiline (green) to CPT-2 (PDB ID: 2H4T), superimposed onto a CPT-2 structure with a bound drug, ST1326 (yellow) (PDB ID: 2FW3).
Residues that differ between mammals and nematodes are shown in gray (L335, S445, Q447, V597, S598, L599, A615, W620, C623, N624), and the
catalytic H372 is shown in orange. C. Interactions perhexiline make with CPT-2 (PDB ID: 2H4T) (P133, F134, M135, H372, D376, G377, V378, L381, S590,
L592, G601). D. The C. elegans protein was used to find similar mammalian sequences with BLASTP and the non-redundant (NR) database. Residues
shown in gray in B are labeled with red asterisks below the sequence. The alignment (using MUSCLE) of the following proteins is shown:
gi|294805368|gb|ADF42518.1 (S. scrofa), gi|296489058|gb|DAA31171.1 (B. Taurus), gi|4503023|ref|NP_000089.1 (H. sapiens), gi|162138915|r-
ef|NP_034079.2 (M. musculus), gi|1850592|gb|AAB48047.1 (R. norvegicus), 2FW3 chain A, Tsp_06820 (T. spiralis), Mh10g200708_Con-
tig108_46414_50093 (M. hapla), prot_Minc00582 (M. incognita), R07H5.2a (C. elegans), gi|308491342|ref|XP_003107862.1 (C. remanei),
gi|341894296|gb|EGT50231.1 (C. brenneri), gi|324506871|gb|ADY42921.1 (A. suum), 14424.m00388 (B. malayi).
doi:10.1371/journal.ppat.1003505.g007
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targets in KEGG Drug and DrugBank could yield false linkages
between drugs and drug targets. For instance, DrugBank links
drug targets and drugs using text-mining programs to search
through abstracts in PubMed, as well as manual inspection by
trained individuals. As the genomes and databases are improved,
the analysis framework outlined here will become more powerful.
Despite limitations of the approach, two out of the six intestinal
helminth drugs in the World Health Organization (WHO) Model
list target enzymes that catalyze chokepoint reactions. The WHO
Model List of Essential Medicines [48] contains a core list of
minimum medicines that are needed for a basic health care
system. The drugs in this list contain the most efficacious, safe, and
cost-effective medicines for certain conditions. The presence of our
predicted chokepoint drugs on this list indicates that chokepoint
reactions may be useful in providing safe and effective treatments.
The two drugs that target chokepoint reactions (listed with their
respective targets) include: Levamisole (EC: 3.1.3.1 and EC:
6.1.1.6) and Praziquantel (EC: 2.5.1.18). The next two, Albenda-
zole (DB00518) and Mebendazole target tubulin, which is not an
enzyme. The remaining drugs, Niclosamide and Pyrantel, were
not in DrugBank or in KEGG Drug and therefore, could not be
identified in our study. In the category of antifilarials by the
WHO, an additional 6 compounds are listed, but only two have
EC associations. The two compounds, Suramin sodium (EC:
3.1.1.4 & 3.5.1.-) and Praziquantel (EC: 2.5.1.18), are both
associated with targets that are enzymes involved in chokepoint
reactions. Some of the enzyme drug targets are not in CommNem,
but are in UniNem. Although it is not on the WHO list,
Metrifonate is used as an insecticide and anthelmintic drug and
targets an enzyme, EC: 3.1.1.7 (CommNem), which is associated
with acetylcholinesterase in a chokepoint reaction.
Considering all anthelmintic drugs, there are also some drugs
that are in KEGG that either do not have ECs associated or are
not known chokepoints. Within KEGG Drug, Diethylcarbama-
zine (DB00711) targets two enzymes: EC: 1.9.3.1 (not in a
chokepoint reaction) and EC: 1.13.11.34 (involved in a chokepoint
reaction) [49]. Nitazoxanide targets EC: 1.2.1.51, which is not a
known chokepoint enzyme [50]. Ivermectin (DB00602) and
piperazine (DB00592) (two popular anthelminths) do not target
enzymes, but target the GABA-A [51] and glutamate-gated
chloride channels [52]. For Thiabendazole (DB00730), the
metabolizing enzyme cytochrome P450 is a chokepoint. Thiaben-
dazole is thought to inhibit fumarate reducatase [53] (EC:
1.3.99.1, which is not a chokepoint in our study), but the precise
mode of action is unknown [54]. Biothionol, Oxamniquine,
Niclosamide, Niridazole, and Triclabendazole are not found in
DrugBank, and KEGG Drug does not have an EC number
associated with them. If DrugBank is searched for drugs used to
treat parasitic infections, eleven out of fifteen drugs used to treat
parasitic infections that also have assigned ECs are chokepoint
reactions in our study. An additional twelve drugs used to treat
parasitic infections do not have ECs associated with them.
Searching DrugBank for insecticides yielded four out of five drugs
that have targets with ECs associated that are chokepoint reactions
(Table S3 in Text S1).
Ideal drug targets in nematodes are proteins found only in
nematodes and not in their host. The enzyme 4-coumarate-CoA
ligase (4CL, EC: 6.2.1.12) is one such enzyme found in the
CommNem group and not in H. sapiens in this study. This enzyme
class has potential to be very interesting for pan-phylum
nematicides. 4CL is involved in many reactions in the phenylpro-
panoid biosynthesis pathway, but the chokepoint compound is
Cinnamoyl-CoA (C00540). Cinnamoyl-CoA feeds directly into the
flavonoid biosynthetic pathway in plants and is also a precursor for
capsaicin synthesis. The role 4CL plays in nematodes is unclear
but it may be involved in host-parasite interactions (due to its
position in the flavonoid pathway in plants) or in the production of
antioxidants (due to its upstream involvement in capsaicin
synthesis, to enable the worm to survive in the host).
During the course of this project, the chokepoint enzymes from
the flatworm Schistosoma mansoni were published, and therefore our
results were compared to theirs [55]. Out of 607 enzymes that
were successfully placed in pathways, 120 were classified as
chokepoint enzymes, and only 107 of these chokepoint enzymes
were unique. From the chokepoint reactions found in KEGG in
our study (2249), 56 chokepoint enzymes overlap with the S.
mansoni chokepoint enzymes. Interestingly, there are many
similarities between the nematode chokepoint reactions found in
this study and the flatworms, with 50 and 33 chokepoint enzymes
intersecting the S. mansoni/UniNem and CommNem sets (respec-
tively). Only 1 chokepoint enzyme (EC:2.3.1.39) in the ParaNem
set overlaps with the S. mansoni set, but it only obtained a target
score of 1.
Several trends between chokepoint enzymes in general and
chokepoint enzymes that have drugs associated with them were
found. The chokepoint enzymes in CommNem and UniNem
could potentially be enriched for drug targets by looking at trends
in the KEGG Drug and DrugBank datasets. For instance,
enzymes may be higher in priority because they were were
significantly enriched in the set of chokepoint enzymes present in
KEGG Drug and DrugBank, compared to AllKEGG and
KEGGChoke. Ligases were significantly depleted relative to
AllKEGG for both DrugBank and KEGG Drugs, so these
enzymes would not be weighted as highly because they are
depleted in databases of known drugs.
Whether the chokepoint compound was a substrate or a product
of the chokepoint reaction did not seem to have any bearing on
whether the enzyme was a good drug target. However, the
pathway population was different between KEGGChoke com-
pared to the DrugBank and KEGG Drug databases. Within the
KEGG Drug and DrugBank databases, enzymes are involved in
more pathways compared to KEGGChoke and AllKEGG. For
KEGG Drug and DrugBank, enzymes involved in just one
pathway are depleted and those involved in more than one are
enriched for enzymes within the drug databases. A significant
observation between the enzymes associated with chokepoint
reactions in the drug databases and the entire list of chokepoint
compounds (consumed and created) for various species is the
position of the chokepoint in the pathway. Chokepoint enzymes
that have known anthelmintic drugs associated with them are
found more often around the first 20% (consumed compounds) or
around 50% (created compounds) of the pathway length, and
chokepoint enzymes that have compounds in KEGG drug
associated with them were located around 70% of the pathway
length. However, the trend did not exist for chokepoint enzymes
associated with compounds in DrugBank, suggesting that this
finding may have been an artifact of KEGG Drug. Before
conclusions are drawn, the test should be expanded to other drug/
protein databases.
Based on the areas studied (where significant differences were
seen between a set of all chokepoint enzymes and the drug
database), we developed a scoring scheme that helped us prioritize
these chokepoint enzyme targets for experimental testing. Many of
the targets can be considered broad spectrum, as these proteins are
found in all 10 nematode genomes. For instance, nucleoside-
triphosphate diphosphatase (EC: 3.6.1.19) scored high on the
prioritized list. This enzyme is inhibited by plant compounds,
lycorine and candimine, in Trichomonas vaginalis, a parasitic
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protozoan, which could make T. vaginalis more susceptible to the
host immune system [56]. In addition, it is also a possible target for
antimicrobial therapy [57]. In S. mansoni, EC: 3.6.1.19 is secreted
and also believed to help the worm evade the immune system of
the host; there is a new class of antischistosoma drugs (N-alkyl-
aminoalkanethiosulfuric acids) that inhibit the enzyme and may
negatively impact schistosoma survival [57]. Another prioritized
target is nucleoside-diphosphate kinase (EC: 2.7.4.6), which is
secreted by T. spiralis and may modulate host cell function [58].
This enzyme has been studied in B. malayi and is expressed during
all parasitic stages in B. malayi, and molecular modeling for drug
targeting has been performed for it in B. malayi [59].
Repositioning or further optimization of existing drugs may
provide a means to obtain much needed anthelmintic drugs at a
faster pace, as many of the drugs already have FDA approval.
Existing drugs-like compounds may yield a faster path to
anthelmintic drugs by providing a known scaffold that may
require some optimization. Many drugs in KEGG Drug and
DrugBank whose targets also hit nematode ECs have immuno-
suppresant, anti-inflammatory, antiviral, and antineoplastic activ-
ity. For example, Levamisole, an anthelmintic drug, is also a
treatment for rheumatoid arthritis [60]. These target proteins may
provide insight into how the parasite evades the immune system
when it infects the host. Further, other targets with drugs that have
immunosuppressant activity may yield a drug that has already
been approved that can be repositioned as an anthelmintic drug.
For instance, Mercaptopurine (DB01033) and Azathioprine
(DB00993) (Table 1), which resulted from the prioritized list of
drug-like compounds from DrugBank, both have immunosup-
pressive properties. In addition, several targets in KEGG Drug
with homology to helminth proteins also have immunosuppressive
activity, including IMP dehydrogenase (EC: 1.1.1.205). Several
chokepoint targets from KEGG Drug with homology to helminth
proteins also have antimalarial and antiprotozoal properties, such
as phospholipase A2 (EC: 3.1.1.4). The corresponding drugs for
various targets are listed in Table S6 in Text S1 and Table S7 in
Text S1.
To find promising drug-like compounds for repositioning (or
ones which hit scaffolds for which further optimization can be
done), drug-like compounds that target chokepoint enzymes were
also prioritized and the best candidates were tested in C. elegans and
2 parasitic nematodes. One compound, Perhexiline (PER)
(DB01074) (1), yielded an EC50 value of 47.3 mM (18.5 ppm)
and caused a slow movement and twitchy phenotype in C. elegans,
as well as a deleterious phenotype in H. contortus and O. lienalis, two
parasitic nematode species. PER is an approved small molecule
drug which is used as a coronary vasodilator and used for angina
treatment [19]. According to DrugBank, PER binds to H. sapiens
carnitine o-palmitoyltransferase I (CPT-1) and carnitine o-
palmitoyltransferase 2 (CPT-2). If PER inhibits CPT-1 or CPT-
2 in living parasites, a drop in fatty acid oxidation can be measured
by oxygen consumption rates experimentally. The dose-dependent
decrease in basal oxygen consumption rates in the C. elegans
exposed to PER (Figure 5A) provides indirect evidence that PER is
acting via its intended mode of action on CPT-1 and CPT-2. In
addition, a comparison of OCR in C. elegans exposed to either
PER, ETO (or both) to an anthelmintic with a different mode of
action would also provide an independent orthogonal confirma-
tion of the similarity of PER and ETO in their possible mode of
action on CPT-1 and CPT-2. Indeed, the lack of an observed
decrease of OCR in C. elegans in the presence of IVM (which
disrupts neurotransmission processes regulated by GluCl activity)
further confirmed our hypothesis (Figure 5). Additionally, tran-
scriptional responses to drugs often carry signatures for drug
physiological mode of action. The transcriptional response to PER
was measured by RNAseq and compared to that of ETO and
IVM. Drugs with a related mechanism of action (i.e., PER and
ETO) cluster together, since similar patterns of pathways are
expected to be significantly perturbed. The clustering we observed
(Figure 6A), as well as a Gene Ontology analysis of upregulated
genes which (among other GO categories) includes peroxisome
and fatty acid beta-oxidation, provides an additional confirmation
of the similarity of PER and ETO in their mode of action (Table
S10 in Text S1). Further experimentation, including in vitro
enzyme assays, binding studies and drug resistance mutants, would
need to be done to validate completely the mode of action and to
move from hit to lead. The compound may need to be altered in
order to increase efficacy.
There are 6 homologs of carnitine o-palmitoyltransferase (EC:
2.3.1.21) in C. elegans. R07H5.2 (cpt-2) is expressed in the adult and
larval intestines of C. elegans and has an embryonic lethal RNAi
phenotype, whereas Y46G5A.17 (cpt-1) does not have an RNAi
phenotype (see below for a detailed explanation) and is expressed
in the intestine, body wall muscle, and rectal gland cells in larva
and in the pharynx, reproductive system, vulval muscle, and body
wall muscle in adults [61]. The chokepoint compound in this
reaction, L-palmitoylcarnitine (L-PC) has been shown to inhibit
the Na/K pump in guinea-pig ventricular myocytes [62] and the
interaction between L-PC and PIP2 in the membrane regulate
KATP channels [63]. A module of the KEGG Fatty Acid
Metabolism pathway map is shown in Figure 7A. Using Autodock
4 [41], perhexiline was docked into the active site of CPT-2 [42]
(Figure 7B). The binding site of perhexiline in CPT-2 does not
overlap with the carnitine group in the ST-1326 based on the
docking calculations, which is consistant with biophysical exper-
iments on CPT-1 [64], which showed competitive inhibition with
respect to palmitoyl-CoA, but non-competitive inhibition with
respect to carnitine. PER binds to residues in the active site that do
not differ between mammals and nematodes (Figure 7D), which
explains its efficacy in different phyla. Differences in residues
between nematodes and mammals are present around the binding
site (Figure 7D), and these differences could be exploited to
generate a specific and more potent inhibitor by extending the
PER molecule into this area.
Two other compounds, Carbidopa (DB00190) (2) and Azelaic
acid (DB00548) (7), also showed deleterious movement phenotypes
in C. elegans. Carbidopa (8) is an approved small molecule that is an
inhibitor of L-DOPA decarboxylase (EC: 4.1.1.28 chokepoint
enzyme), which prevents the conversion of levodopa to dopamine
(Figure 8). Carbidopa is used in the treatment of Parkinson’s
disease to reduce the side effects of levodopa, but has no anti-
Parkinson actions by itself [19]. L-DOPA decarboxylase was also
found to be a chokepoint in flatworm [55], and Methyldopa (9)
has been found to inhibit enzyme activity in schistosoma extracts
[65]. Methyldopa and carbidopa only differ by one amino group
(Figure 3B). Azelaic acid is also an approved drug that targets, 3-
oxo-5-alpha steroid 4 dehydrogenase (EC: 1.3.99.5 chokepoint
enzyme), as well as thioredoxin reductase, tyrosinase, and DNA
polymerase I [19]. Typically, azelaic acid is used to treat acne and
has antimicrobial properties.
High throughput RNAi studies in C. elegans can provide
evidence that an enzyme has an important in vivo function [66],
suggesting that targeting that enzyme using a drug would likely
have a deleterious effect on the worm. Similar phenotypes
observed for a drug treatment and RNAi (or gene mutation)
provide support that the drug is specifically inhibiting the gene
product targeted by RNAi. However, high-throughput RNAi data
needs to be considered with caution [66,67,68], and thus it was not
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possible to incorporate it into our chemogenomic pipeline. There
are a number of reasons why high throughput RNAi experiments
can fail to generate a phenotype. One biological reason is that
there is a family of genes that encode the enzymatic activity, and
knockdown of any single gene will have no effect due to genetic
redundancy. This appears to the case for L-DOPA decarboxylase
(EC: 4.1.1.28), which is encoded by three paralogs (K01C8.3,
ZK829.2, and C05D2.3) that do not show single gene RNAi
phenotypes. In some cases however, gene family members can
have essential functions, due to divergent protein sequences,
subcellular compartmentalized functions and/or unique expres-
sion behavior, which may explain why cpt-2 RNAi displays a
strong phenotype. Other biological reasons why RNAi may fail to
display a phenotype include RNAi resistance for the genes or that
the relevant functional cell type is largely resist to RNAi (e.g.
neurons). Additionally, high throughput RNAi in C. elegans has,
methodologically, a relatively high rate of false negatives. In
contrast, the false positive rate for RNAi in C. elegans is generally
low, but can occur due to the libraries containing some incorrect
RNAi clone IDs. Thus while high-throughput RNAi data can be
used as a starting point, gene product hits from chemogenomic
pipelines must be individually tested experimentally, including
verification of RNAi clone identity, assessment of the extent of
knockdown, or through analysis of gene deletions, if available.
Finally, when comparing phenotypes generated by RNAi (or
mutant) relative to drug treatment, the extent of gene product loss
of function and drug-mediated inhibition need to be comparable,
with consideration of the developmental stage that is being
examined. For the compounds with hits, further experimentation
that includes other life cycle stages would need to be performed to
determine if the compounds should progress to advanced testing
and move it from ‘hit’ to ‘lead’. The compound may also need to
be modified to increase efficacy.
This study has yielded many interesting lead drug target hits
and drug-like compounds that should be explored further that
could potentially yield a next-generation anthelmintic/nematicide
or novel drug target.
Conclusions
In this study, we report chokepoint reactions and enzymes that
are common to all 10 studied species of nematodes, as well as
chokepoint reactions and enzymes that encompass the union of the
10 nematode species. This study goes further than previous studies
to try to understand features of chokepoint enzymes that are
successful drugs targets, then uses available diverse information to
prioritize the nematode chokepoint enzymes for those that are
good drug candidates. Scoring high on the prioritized list are
targets that are under investigation for treatment of parasites,
indicating that the list contains reasonable targets that should be
investigated further. In addition, KEGG Drug and DrugBank
were examined for existing drugs that could be repositioned or
optimized as anthelmintic drugs. Three of the seven compounds
were experimentally tested and show efficacy in C. elegans, and one
of these three (Perhexiline) shows efficacy in two nematode species
with distinct modes of parasitism. A suggested mode of action was
also outlined for Perhexiline. Computational modeling results
suggest opportunities for higher affinity and specificity using this
compound as a starting point. The list of prioritized drug targets
and drug compounds has enormous potential for the development
of new and urgently-needed anthelmintic drugs and pesticides.
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Text S1 Supporting tables. Table S1. ECs of the 169
chokepoints from the intersection of the nematode deduced
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reactions (chokepoint enzymes, with its substrate and product) are highlighted in red. A. Pathway Maps for Steroid Hormone Biosynthesis (ko00140).
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within KEGG (KEGGChoke) and B. enzymes from all of KEGG
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either KEGGChoke or AllKEGG using Fisher’s Exact Test. The
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ECs from D. melanogaster; DrugBank, ECs from DrugBank; KEGG
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AllKEGG and B. KEGG Drug, DrugBank, KEGGChoke, and
AllKEGG. CommNem, intersection of ECs; UniNem, set of all
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